Login
$TVRD
$1.10 -$0.08 (6.78%) Live

$TVRD 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition

HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to tre...

14 Aug 2026 8-K: Results of Operations and Financial Condition

Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations

30 Jul 2026 8-K: Regulation FD Disclosure

This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat...

17 Jul 2026 8-K: Other Events

We have acted as counsel to Tvardi Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate...

07 Jul 2026 8-K: Regulation FD Disclosure

This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat...

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2026, Tvardi Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the four proposals set forth below. A more detailed des...

08 May 2026 8-K: Results of Operations and Financial Condition

Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June

31 Mar 2026 8-K: Results of Operations and Financial Condition

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

06 Mar 2026 8-K: Other Events

Tvardi Therapeutics, Inc. (the “Company”) has set June 9, 2026 as the date for the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Proposals of stockholders intended to be presented at the 2026 Annual Meeting p...

16 Jan 2026 8-K: Regulation FD Disclosure

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our expectation...

18 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 16, 2025, the Board of Directors of Tvardi Therapeutics, Inc. (the “Company”) approved one-time retention compensation for certain of the Company’s employees, as recommended by the Compensation Committee of the Board, includi...

19 Nov 2025 8-K: Regulation FD Disclosure

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our expectation...

13 Nov 2025 8-K: Results of Operations and Financial Condition

On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026

14 Oct 2025 8-K: Other Events

Tvardi Therapeutics Provides Update on Preliminary Data from

14 Aug 2025 8-K: Results of Operations and Financial Condition

On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025

14 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

On July 8, 2025, Shaheen Wirk resigned as a member of the Board of Directors (the “Board”) of Tvardi Therapeutics, Inc. (the “Company”). Dr. Wirk’s decision to resign from the Board was not the result of any disagreement with the Company...

09 Jun 2025 8-K: Other Events

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our expectation...

27 May 2025 8-K: Regulation FD Disclosure

Topline data from the REVERTIPF trial anticipated in 4Q 2025

13 May 2025 8-K: Results of Operations and Financial Condition; Changes in Registrant's Certifying Accountant

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

15 Apr 2025 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +8 more

(a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support